| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |